Dermatology drugmaker Biofrontera's Q4 revenue rises to record high on Ameluz strength
Overview
US biopharma firm's Q4 revenue rose 36% yr/yr to record high, driven by Ameluz sales
Company posted Q4 net income of $5.6 mln, reversing prior-year loss
Gross margin improved to 82.4% in Q4, reflecting lower costs after strategic transaction
Outlook
Company expects full annualized benefits of new cost structure to be realized in 2026
Biofrontera anticipates shift toward sustained profitability and cash flow breakeven in 2026
Result Drivers
AMELUZ SALES EXECUTION - Co said record Q4 revenue growth was primarily driven by strong Ameluz sales execution and pricing adjustment
COST STRUCTURE TRANSFORMATION - Transition to lower earnout structure after strategic transaction with Biofrontera AG materially reduced cost of goods sold
LEGAL EXPENSES - Higher legal costs increased operating expenses in Q4
Company press release: ID:nGNXbdZf78
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Beat | $17.10 mln | $16.15 mln (2 Analysts) |
Q4 Net Income |
| $5.60 mln |
|
Q4 Adjusted EBITDA |
| $4.90 mln |
|
Q4 Operating Expenses |
| $12.50 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Biofrontera Inc is $6.00, about 590.8% above its March 18 closing price of $0.87
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
